Pharmaceutical Technology

APRIL 13, 2023

Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. We are pleased with Biogen’s decision to license ATV: Aβ and we are hopeful this will foster the development of next-generation anti-Aβ therapeutics.”

Licensing 130

Licensing Licensing Antibody Clinical Trials 130

Pharmaceutical Technology

JANUARY 2, 2023

South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.

Licensing 130

Licensing Licensing Sales Development 130

Pharmaceutical Technology

JULY 7, 2023

Shorla Oncology has signed a licensing agreement with an undisclosed drug UK firm for a chemotherapy drug, PIP-101.

Licensing 130

Licensing Licensing Drugs 130

BioSpace

SEPTEMBER 13, 2023

The company declined to exercise the license option for Harpoon Therapeutics’ TriTAC HPN217 program for multiple myeloma, which targets B cell maturation antigen, or BCMA.

Licensing 105

Licensing Licensing 105

Pharmaceutical Technology

MARCH 28, 2023

On March 27, OncoVerity announced the acquisition of worldwide licensing rights of the anti-CD70 monoclonal antibody cusatuzumab from the biotech argenx. Alongside this, the company closed a $30 million Series A, which came from both argenx and the venture of UCHealth and the University License Equity Holdings.

Licensing 130

Licensing Licensing Development Antibody 130

Pharmaceutical Technology

MAY 3, 2023

Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.

Licensing 130

Licensing Licensing Development Sales 130

Pharmaceutical Technology

DECEMBER 5, 2022

Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US.

Licensing 130

Licensing Licensing Production Marketing 130

Drug Discovery World

AUGUST 2, 2023

Renaissance Pharma has announced its first development programme focused on Hu14.18, a humanised anti-GD2 monoclonal antibody (mAb), licensed from St Jude Children’s Research Hospital for the treatment of newly diagnosed high-risk neuroblastoma. ” The post Renaissance Pharma licenses Hu14.18

Licensing 98

Licensing Licensing Antibody Trials 98

Pharmaceutical Technology

JULY 11, 2023

Astellas Pharma has entered into an agreement to license 4DMT's R100 vector for a genetic target associated with rare ophthalmic ailments.

Licensing 100

Licensing Licensing Genetics 100

Bio Pharma Dive

MAY 12, 2021

The drug, which Biogen had an option to license, is one of two in the biotech's pipeline for a condition that has had few new treatments developed.

Licensing 246

Licensing Licensing Drugs Development 246

Pharmaceutical Technology

JUNE 19, 2023

Bio-Thera Solutions and Biomm have entered a licensing and supply agreement for Bio-Thera’s BAT2206, a ustekinumab biosimilar. Biomm will gain exclusive rights for the distribution and marketing in Brazil of the proposed biosimilar to Janssen’s Stelara.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

APRIL 13, 2023

ImaginAb will be responsible for licensing and supplying the clinical doses of 89Zr crefmirlimab berdoxam, its investigational CD8 ImmunoPET tracer, to Leucid Bio. Biotechnology company ImaginAb has entered into a new non-exclusive licence and supply agreement with Leucid Bio for CD8 ImmunoPET technology.

Licensing 130

Licensing Licensing Gene Therapy Gene 130

Bio Pharma Dive

MARCH 6, 2023

The Swiss drugmaker's decision is the latest in a string of partnership announcements for the gene therapy maker, which aims to bounce back from past research failures.

Gene Therapy 274

Gene Therapy Gene Licensing Licensing 274

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics.

Protein 130

Protein Licensing Licensing Development 130

Pharmaceutical Technology

JUNE 20, 2023

Santhera Pharmaceuticals and Catalyst Pharmaceuticals have signed an exclusive licence and collaboration deal for Santhera’s vamorolone in the US, Canada and Mexico. Catalyst Pharmaceuticals will gain exclusive rights to commercialise vamorolone across the region.

Licensing 246

Licensing Licensing Drugs Medicine 246

Pharmaceutical Technology

APRIL 25, 2023

German biotechnology firm 3B Pharmaceuticals (3BP) has entered into a licensing agreement with Novartis Innovative Therapies for its fibroblast activation protein (FAP)-targeting peptide technology. 3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments.

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

BioPharma Reporter

SEPTEMBER 25, 2023

MC2 Therapeutics has acquired the exclusive licensing rights for Regranionâs RGRN-305, a new treatment for hidradenitis suppurativa (HS).

Licensing 52

Licensing Licensing Drugs Regulation 52

Pharmaceutical Technology

JANUARY 23, 2023

The post Takeda signs licensing agreement with HUTCHMED for fruquintinib appeared first on Pharmaceutical Technology. HUTCHMED commenced a rolling submission of a New Drug Application (NDA) to the US FDA for fruquintinib in December last year. The submission is planned to be completed in the first half of this year.

Licensing 130

Licensing Licensing Medicine Drugs 130

Pharmaceutical Technology

JULY 28, 2022

The post Melinta and Cidara sign licensing deal for rezafungin appeared first on Pharmaceutical Technology. “We will continue to aggressively pursue portfolio expansion that aligns with our mission of providing innovative therapies for acute and life-threatening illnesses.”.

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Drug Patent Watch

JULY 26, 2023

While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out that they keep a list on their website, so I… The post List of NIH-Licensed Technologies appeared first on DrugPatentWatch - Make Better Decisions.

Licensing 52

Licensing Licensing 52

Pharma Mirror

OCTOBER 1, 2022

HK), an innovation and R&D-driven pharmaceutical company; today announced that they have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278. Simcere will retain all rights to develop and commercialise SIM0278 within Greater China.

Licensing 130

Licensing Licensing Protein Drugs 130

Pharmaceutical Technology

OCTOBER 4, 2022

The post Shionogi and MPP enter Covid-19 antiviral licensing deal appeared first on Pharmaceutical Technology. In March, the company and the Japanese Ministry of Health, Labor and Welfare (MHLW) entered an agreement to supply courses of S-217622 for Covid-19 in the country.

Licensing 147

Licensing Licensing Clinical Trials Clinical Trials 147

Outsourcing Pharma

JULY 18, 2023

Roche has entered a licensing and collaboration deal with the U.S. company KSQ Therapeutics to co-develop KSQâs lead cancer drug, which is designed to sabotage the DNA repair mechanisms of cancer cells.

DNA 84

DNA Licensing Licensing Drugs 84

AuroBlog - Aurous Healthcare Clinical Trials blog

MARCH 20, 2023

Empowering of the Central Drugs Standard Control Organisation (CDSCO) through centralisation of drug licensing may not be the path to improve the quality of drugs manufactured in the country both for domestic and international markets, says SME Pharma Industries Confederation (SPIC), the apex organisation of small and medium pharma industries in the (..)

Drugs 146

Drugs Licensing Licensing Manufacturing 146

Pharmaceutical Technology

JANUARY 6, 2023

The post Adcendo and Duality Biologics sign license deal for ADC platform appeared first on Pharmaceutical Technology. “We believe the collaboration reflects the mutual recognition of each party’s unique strengths in ADC discovery and development and look forward to supporting the development of innovative ADC drugs.”.

Licensing 130

Licensing Licensing Antibody Drugs 130

Pharma Mirror

APRIL 18, 2023

The license allows Sterling to manufacture antibody-drug conjugates (ADCs) for clinical use in its current Good Manufacturing Practices (cGMP) compliant manufacturing facility in Deeside, UK.

Antibody 130

Antibody Licensing Licensing Drugs 130

Scienmag

APRIL 28, 2021

— Licensing expert Bob Westervelt, who has worked to transfer Sandia National Laboratories technologies in the medical, solar and hydrogen production fields, received the 2021 Outstanding Technology Transfer Professional Award from the Federal Laboratory Consortium.

Licensing 95

Licensing Licensing Production Engineer 95

Bio Pharma Dive

OCTOBER 12, 2022

The drugmaker’s decision to grab rights to the shot deepens its ties with the COVID-19 vaccine developer and comes weeks before a key data release.

Vaccination 322

Vaccination Vaccine Licensing Licensing 322

pharmaphorum

JANUARY 10, 2023

Astellas has licensed rights to a drug developed by Selecta Biosciences that could make more patients eligible for treatment with its gene therapy for inherited neuromuscular disorder Pompe disease. The post Astellas licenses companion drug for Pompe gene therapy appeared first on.

Gene Therapy 119

Gene Therapy Gene Licensing Licensing 119

Pharmaceutical Technology

MAY 2, 2023

Immatics will receive $15m from the global license agreement and is in line for a further $490m in milestone payments for this candidate. This news comes a few weeks after BMS signaled an increased focus on cell therapy manufacturing with a takeover of former Novartis plant to boost viral vector production for T-cell therapies.

Licensing 130

Licensing Licensing Gene Editing Gene 130

Pharma Mirror

JANUARY 26, 2021

But, you are finally here about to get your nursing license in the state of Georgia. When applying for a nursing license or getting your old one renewed, you might face some trouble if the background check doesn’t show up clean. If you’re facing criminal charges or have gone through a.

Nurses 130

Nurses Licensing Licensing 130

pharmaphorum

AUGUST 15, 2023

Pharma incensed by EU's compulsory licensing proposal Phil.Taylor Tue, 15/08/2023 - 08:41 Bookmark this

Licensing 72

Licensing Licensing 72

Fierce Pharma

FEBRUARY 24, 2023

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license esagonowsky Fri, 02/24/2023 - 09:18

Vaccination 145

Vaccination Vaccine Licensing Licensing 145

Pharmaceutical Technology

MARCH 23, 2023

Biohaven has purchased the exclusive global rights for oral, brain-penetrant dual Tyrosine Kinase 2 (TYK2)/Janus Kinase 1 (JAK1) inhibitor, BHV-8000 (previously TLL-041), which treats immune-mediated brain disorders , from Hangzhou Highlightll Pharmaceutical.

Licensing 263

Licensing Licensing Clinical Development Trials 263

Drug Discovery World

MAY 8, 2023

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021.

Licensing 52

Licensing Licensing Drugs Development 52

BioSpace

DECEMBER 21, 2022

Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.

Licensing 97

Licensing Licensing Antibody Drugs 97

Fierce Pharma

AUGUST 30, 2023

After settling a patent case with Vivitrol maker Alkermes, Teva has gained a license to launch its generic version of the opioid dependence and alcohol dependence med years ahead of the drug's pate | Under the patent settlement, Teva will be able to launch its generic two years ahead of the 2029 patent expiration for Vivitrol.

Licensing 72

Licensing Licensing Drugs 72